Lakefront Biotherapeutics (GLPGF) Notes Payables (2020)
Lakefront Biotherapeutics' (GLPGF) quarterly Notes Payables came in at $83460.3 in Q4 2020.
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) Notes Payables (2020) Analysis & Trends
Lakefront Biotherapeutics (GLPGF) has reported Notes Payables for 1 consecutive years, with $83460.3 the latest figure, recorded in Q4 2020.
- On a quarterly basis, Notes Payables changed N/A year-over-year to $83460.3 in Q4 2020; TTM through Dec 2020 was $83460.3, a N/A change from a year earlier, with the FY2020 full-year figure at $83460.3, changed N/A from the prior year.
- Notes Payables was $83460.3 for Q4 2020 at Lakefront Biotherapeutics.
- Over five years, Notes Payables peaked at $83460.3 in Q4 2020 and troughed at $83460.3 in Q4 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.20 Bn | 198.21 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.83 Bn | 178.65 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.47 Bn | 124.61 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.56 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.40 Bn | 1.37 Bn |
| 6 | Moderna | 54.65 Bn | 49.51 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn |
| 8 | Biogen | 31.42 Bn | 30.13 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.21 Bn | 30.21 Bn | 1.16 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn |